Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company specializing in biomarkers and augmented intelligence (AI) algorithms to locate chronic low back pain, has announced a new initiative aimed at enhancing the personal injury and workers compensation market in New Jersey. The company has partnered with Dr. Justin Kubeck, an orthopedic surgeon and founder of Ocean Pain and Spine in Toms River, NJ, to spearhead this effort.
Dr. Kubeck will lead a statewide network of providers to utilize Aclarion's Nociscan technology, which aims to improve the objective evaluation of chronic low back pain patients within the complex personal injury and workers compensation ecosystem. This initiative is expected to streamline the process of determining appropriate treatments and financial compensation for patients suffering from injury.
In New Jersey, the average settlement for personal injury claims involving neck and back injuries is approximately $918,967. On a national scale, work-related accidents resulting in neck and back injuries have an average settlement of $148,750. These significant financial implications underscore the importance of accurate and objective diagnostics in these cases.
Dr. Kubeck emphasized the critical need for objective and definitive diagnoses in personal injury and workers compensation claims, which often involve legal challenges. He stated, "The use of Nociscan can be a powerful objective measurement tool to provide a strong case for supporting an appropriate treatment pathway." Over the coming months, Dr. Kubeck plans to educate judges and lawyers involved in these claims about the value of Nociscan in improving the evaluation process.
Nociscan technology measures biomarkers in the lumbar disc that correlate with pain and structural integrity, providing important objective data for healthcare providers. This data can be crucial in formulating and defending recommended treatment plans, possibly influencing the size of settlements, especially in cases where surgical intervention might be necessary.
Ryan Bond, Chief Strategy Officer of Aclarion, highlighted the broader implications of this initiative, noting that success in New Jersey could pave the way for similar programs across the United States. "We believe this population is the perfect fit for the use of advanced biomarker identifications correlated to pain and available exclusively through the Nociscan platform," Bond said.
By leveraging AI and biomarker technology, Aclarion aims to bring precision and clarity to the diagnosis and treatment of chronic low back pain, which could have far-reaching effects on the personal injury and workers compensation landscape. This initiative not only promises to enhance patient care but also to provide a more robust foundation for legal adjudications related to these claims.
